I'm afraid it seems to be more of the same, just expanded to take in the GLP-1s etc. The committee appears to be most interested in medicines/pharmaceuticals, and that's what they focus on.
I was a bit surprised that there seems to be nothing added about planning with the patient for coming off Wegovy/Ozempic/Mounjaro etc. I don't know if this indicates either that people will stay on these indefinitely or that they just haven't thought that anything else is needed. Or something else entirely.
The "T2s should eat what everybody else eats" recommendation is unchanged, as is the bit about not giving glucose lowering meds to people on a keto/low-carb diet, because of the risk of hypos. So there's a tacit acknowledgement that a keto/low carb diet will lower BG, but still nothing about actively using dietary changes as a main intervention.
Of course, were they to do that, they'd have to go right against the Eatwell guide recommendations, and I can't see that happening. The medical establishment will hold the currently accepted and failing low-fat line as they have for the last forty years - until they're all ready to change everything.